8.3853
10.2925
1
Suitability:
This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.
We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in flexi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.
But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.
Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.
Taxability of earnings:
Capital gains
Dividends
Please wait...
Please wait...
| YTD | 1-Day | 1-W | 1-M | 3-M | 6-M | 1-Y | 3-Y | 5-Y | 7-Y | 10-Y | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ITI Pharma and Healthcare Fund Reg-G | -16.05 | -0.55 | 1.69 | -2.92 | -10.24 | -15.07 | -- | -- | -- | -- | -- |
| S&P BSE Healthcare TRI | -17.13 | -0.33 | 1.98 | -3.57 | -11.67 | -16.02 | -- | -- | -- | -- | -- |
| Equity: Sectoral-Pharma | -15.95 | -0.33 | 1.75 | -3.12 | -11.08 | -14.74 | -- | -- | -- | -- | -- |
| Rank within category | 9 | 13 | 9 | 6 | 2 | 9 | -- | -- | -- | -- | -- |
| Number of funds in category | 14 | 14 | 14 | 14 | 14 | 14 | 11 | 8 | 4 | 3 | 3 |
As on 29-Jun-2022
| Fund name | Rating | Launch Date | 1-Year Return | 3-Year Return | 5-Year Return | Expense Ratio | Assets (Cr) |
|---|---|---|---|---|---|---|---|
| ITI Pharma and Healthcare Fund - Regular Plan | Nov-21 | -- | -- | -- | 2.52% | 159 | |
| Nippon India Pharma Fund | Jun-04 | -14.27 | 22.55 | 15.56 | 1.95% | 4,516 | |
| ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund | Invest Now | Jul-18 | -11.97 | 22.98 | -- | 2.14% | 2,316 | |
| Mirae Asset Healthcare Fund - Regular Plan | Invest Online | Jul-18 | -10.35 | 26.00 | -- | 2.10% | 1,692 | |
| SBI Healthcare Opportunities Fund | Invest Online | Jul-99 | -13.05 | 22.52 | 10.07 | 2.13% | 1,638 |
| Best Performance | Worst Performance | |||
|---|---|---|---|---|
| Return (%) | Period | Return (%) | Period | |
| Week | 4.82 | 24-Dec-2021 - 31-Dec-2021 | -6.46 | 02-May-2022 - 10-May-2022 |
| Month | 8.01 | 07-Mar-2022 - 06-Apr-2022 | -10.51 | 12-Apr-2022 - 12-May-2022 |
| Quarter | -0.37 | 24-Feb-2022 - 26-May-2022 | -11.48 | 25-Nov-2021 - 24-Feb-2022 |
| Year | -- | - | -- | - |
| Mean | Std Dev | Sharpe | Sortino | Beta | Alpha | |
|---|---|---|---|---|---|---|
| ITI Pharma and Healthcare Fund Reg-G | -- | -- | -- | -- | -- | -- |
| S&P BSE Healthcare TRI* | 20.60 | 22.31 | 0.77 | 1.52 | -- | -- |
| Equity: Sectoral-Pharma* | 22.83 | 20.27 | 0.96 | 1.93 | 0.89 | 4.17 |
| Rank within category | -- | -- | -- | -- | -- | -- |
| Number of funds in category | -- | -- | -- | -- | -- | -- |
The Risk Measures have been calculated using calendar month returns for the last three years.
As on
* As on 31-May-2022
Please wait...
| Number of Stocks | 31 |
| Top 10 Stocks (%) | 70.37 |
| Top 5 Stocks (%) | 47.88 |
| Top 3 Sectors (%) | 99.30 |
| Portfolio P/B Ratio | 4.15 |
| Portfolio P/E Ratio | 32.83 |
| Fund | Category | |
|---|---|---|
| Average Mkt Cap (Rs Cr) | 36,567 | 55,629 |
| Giant (%) | 20.24 | 19.21 |
| Large (%) | 28.17 | 38.04 |
| Mid (%) | 39.15 | 35.58 |
| Small (%) | 12.44 | 7.07 |
| Tiny (%) | -- | 0.73 |
Please wait...
Indicates an increase or decrease or no change in holding since last portfolio
Indicates a new holding since last portfolio
As on 31-May-2022
— Hetal Gada since 29-Apr-2022
Education: Ms. Gada has done MBA (Finance)
Experience: Prior to joining ITI AMC, she worked with Centrum where she handled research in auto and consumer sector. Prior to that, she worked with Elara Securities for 2 years and CRISIL for more than 3 years, both where she handled research on various sectors including metals.
Funds Managed:
— Pratibh Agarwal since 29-Apr-2022
Education: Mr. Agarwal is a Masters of Technology (IIT Kanpur)
Experience: Prior to joining ITI Asset Management, he has worked with Nippon India Asset Management as Research Associate, Yoctel Solutions Ltd. as Senior Consultant, Alcatel Lucent Ltd as Engineer.
Funds Managed:
— Rohan Korde since 18-Oct-2021
Education: Mr. Korde is a Masters in Management Studies (Finance), Bachelor of Commerce
Experience: Prior to joining Asset Management Limited, he has worked with BOB Capital Markets as Vice President Research, Prabhudas Lilladher as Vice President Research and Anand Rathi Share & Stock Brokers as Vice President Research.
Funds Managed:
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
| Min. Investment (₹) | 5,000 |
| Min. Addl Investment (₹) | 1,000 |
| Min. SIP Investment (₹) | 500 |
| Min. No of Cheques | 12 |
| Min. Withdrawal (₹) | 1,000 |
| Min. Balance (₹) | -- |
| Lock-in Period | Not Applicable |
| Exit Load | 1% for redemption within 365 days |
| Fund House: | ITI Mutual Fund |
| Launch Date: | 08-Nov-2021 |
| Return Since Launch: | -13.81% |
| Benchmark: | NIFTY Healthcare TRI. |
| Riskometer: | Very High |
| Type: | Open-ended |
| Assets: | ₹ 159 Cr (As on 31-May-2022) |
| Expense: | 2.52% (As on 31-May-2022) |
| Risk Grade: | -- |
| Return Grade: | -- |
| Turnover: | -- |
AMC: ITI Asset Management Ltd.
Address: ITI Asset Mangement Limited, ITI House, Building no. 36, Dr. R. K. Shirodkar Marg, Parel, Mumbai - 400012
Phone: 022-66214999
Email: [email protected]
Website: http://www.itiamc.com
Registrar & Transfer Agent: KFin Technologies Ltd.
Address: 303, Vamsee Estates, Opp. Big Bazaar, Ameerpet, Hyderabad - 500016
Phone: 040-44857874
Email: [email protected]
Website: www.karvymfs.com
You have reserved a spot
Fri, 01-Jul-2022
12:30 PM - 12:45 PM